Top Markets
#1 MowCat MowCat +369.00%
#2 龙虾 (Lobster) 龙虾 (Lobster) +66.03%
#3 SODAX SODAX +51.45%
#4 Cortex Cortex +32.57%
#5 DexNet DexNet +23.19%
#6 OpenEden OpenEden +19.26%
#7 BNB Attestation Service BNB Attestation Service +17.78%
#8 MANTRA MANTRA +17.64%
#9 MarsCoin MarsCoin +17.59%
#10 Akedo Akedo +17.05%
Coin of the day
MowCat MowCat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Classement en actions #7189
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Prix de l'action
$38.45
Capitalisation boursière
$1.68B
Changement (1 jour)
-1.24%
Changement (1 an)
50.36%
Pays
KR
Échange D&D Pharmatech (347850)

Catégorie

Healthcare
Bénéfices pour D&D Pharmatech (347850)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de D&D Pharmatech, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour D&D Pharmatech de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH